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The Minimalist Approach
for Transcatheter Aortic
Valve Replacement in
High-Risk Patients*
Danny Dvir, MD,† Rajiv Jhaveri, MD,‡
Augusto D. Pichard, MD†
Washington, DC
The Rouen Group needs to be congratulated for an impres-
sive series of transcatheter aortic valve replacement (TAVR)
cases performed with the “minimalist approach”: no general
anesthesia (GA), no transesophageal echocardiography
(TEE) guidance. Almost exactly 1 decade ago, in April
2002, Professor Alain Cribier led the first human TAVR
performed in a compassionate case and did it with the
patient under conscious sedation (CS) and local anesthesia
(1). Aortic valve implantation with a percutaneous ap-
proach obviates the need for sternotomy, cardiopulmo-
nary bypass, and manipulation of the ascending aorta.
This approach might also eliminate the need for tracheal
intubation and GA.
See page 461
In this issue of JACC: Cardiovascular Interventions, Du-
rand et al. (2)—from the same pioneering group in Rouen,
France—share their experience of performing transfemoral
TAVR in 151 consecutive cases with the Edwards SAPIEN
and SAPIEN XT transcatheter heart valves (Edwards
Lifesciences, Irvine, California) with exclusively CS with
modest doses of intravenous (IV) midazolam and nalbu-
phine and fluoroscopic guidance, without TEE. The com-
bined 30-day safety endpoint was reached in 15.9%, includ-
ing a death rate of 6.6%, comparable to other large TAVR
series. Conversion to emergent cardiovascular surgery was
performed in 5 cases (3%) and only when using the old
SAPIEN version (Edwards Lifesciences). Conversion to
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isclose.GA in the catheterization laboratory was used in only 1
case. In no patient was GA needed due to complications of
IV sedation or lack of patient cooperation.
In the United States most TAVRs are performed with
GA. In a recent survey exploring anesthetic practices during
transfemoral TAVR, only 5% of the 61 North American
centers employ CS routinely, whereas in Europe 68.4% of
centers are now performing TAVR under CS (Bufton K et
al., personal communication, January 2012).
The minimalist approach of local anesthesia and CS is
obviously attractive in frail, elderly, high-risk patients. It is
assumed that when using minimal amounts of sedative
agents, the hemodynamic effects attributable to these drugs
will be minimal as well. Although inotropic requirements to
correct hemodynamic changes secondary to procedural in-
terventions, such as rapid atrial pacing and balloon valvu-
loplasty, cannot be avoided, the overall need for inotropes
should be lower. Conscious sedation allows the monitoring
of neurological status during the procedure, considered
important because of the high stroke rate. Conscious seda-
tion also offers evaluation of pain during dilator and sheath
placement in the femoral artery. This evaluation plays an
important role in knowing when to stop, because pushing
the dilator or sheath in this scenario might lead to vascular
complication. When CS with minimal sedation is used,
patients are awake at the end of the procedure; thus, time
spent in the intensive care unit and in-hospital is mini-
mized. Moreover, because many of these high-risk patients
have chronic pulmonary disease, complications of prolonged
ventilation are avoided.
Anesthetic management during TAVR procedures has
been the subject of controversy. Most of the important trials
and large registries, unfortunately, do not give data on
anesthetic management during the procedures. There are
only a few trials designed to evaluate the appropriate
anesthetic management during transfemoral TAVR (3–7).
Most publications fail to provide details with regard to the
amounts and types of drugs used for IV sedation or the
depth of sedation achieved or targeted. Thus, it is difficult to
make an informed evidence-based choice about the best
anesthetic management practice in this group of patients.
One large registry of 663 TAVR cases included data
contrasting CS with GA, which showed that the mortality
rate in the CS group was lower than in the GA group (15%
vs. 23%, p  0.02) (8). Nevertheless, the anesthetic ap-
proach was not an independent predictor for mortality after
multivariate analysis. In a recent trial by Bergmann et al.
and in several other nonrandomized trials (3–7), CS showed
similar clinical results compared with GA. A similar expe-
rience was reported in endovascular aortic aneurysm repair,
with shorter procedural time and hospital stay in those with
CS as compared with GA (9).
In our center most of the transfemoral TAVR procedures
are performed with the “Rouen Approach” employing CS.
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469All of our patients had TEE guidance, however, as man-
dated by the PARTNER protocol. Transesophageal echo-
cardiography has been performed under CS in our cathe-
terization laboratory for more than 20 years. Many centers
prefer GA due to the presence of a TEE probe with its high
level of nociceptive stimulation. Our cardiac team, including
anesthesiologists, does not see TEE as a mandatory indica-
tion for intubation. We previously reported a series of
consecutive high-risk patients undergoing transfemoral
TAVR under GA or CS (10). Procedures performed under
CS produced a lower in-hospital death rate, shorter proce-
dure duration, and shorter hospital stay than those per-
formed under GA (Fig. 1 in Durand et al. [2]). Among the
first 230 patients at our center, 158 had the device inserted
through the iliofemoral vessels. Twenty patients (12.7%)
converted to GA. Baseline clinical characteristics of the 2
groups were similar, except for higher logistic EuroSCORE
(European System for Cardiac Operative Risk Evaluation)
in the CS group (39.6  19.7 vs. 31.1  18.5, p  0.02).
Is CS a better approach for most patients undergoing
transfemoral TAVR? The results depicting the safety of CS
come from an experienced team and might not be repro-
ducible for other groups, especially at the beginning of their
learning curve. Moreover, because all the data we have—
including that from Durand et al. (2)—come from nonran-
domized trials, we should view it as “hypothesis generating”
only. It is time to critically evaluate the anesthetic tech-
niques to guide the anesthesiologists who care for these
patients.
Although the Rouen Group had an anesthesiologist
available, he/she was not present in the catheterization
laboratory. In our group the cardiac anesthesiologist is in
charge of CS and is an active member of the team managing
the patient during TAVR. We support the message coming
from Rouen and encourage TAVR centers to collect
anesthesia-related data to help us make an educated choice
when selecting the optimal anesthetic approach for each of
the patient subgroups undergoing these procedures.
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